Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Non Operating Income (2022 - 2025)

Stoke Therapeutics has reported Non Operating Income over the past 4 years, most recently at $3.5 million for Q4 2025.

  • Quarterly results put Non Operating Income at $3.5 million for Q4 2025, up 1643.78% from a year ago — trailing twelve months through Dec 2025 was $7.0 million (up 103.8% YoY), and the annual figure for FY2025 was $13.7 million, up 5648.58%.
  • Non Operating Income for Q4 2025 was $3.5 million at Stoke Therapeutics, up from $3.5 million in the prior quarter.
  • Over the last five years, Non Operating Income for STOK hit a ceiling of $3.6 million in Q2 2024 and a floor of -$7.3 million in Q4 2023.
  • Median Non Operating Income over the past 4 years was $41500.0 (2022), compared with a mean of $308875.0.
  • Biggest five-year swings in Non Operating Income: plummeted 354.72% in 2023 and later soared 12278.57% in 2025.
  • Stoke Therapeutics' Non Operating Income stood at -$1.6 million in 2022, then plummeted by 354.72% to -$7.3 million in 2023, then surged by 102.76% to $201000.0 in 2024, then soared by 1643.78% to $3.5 million in 2025.
  • The last three reported values for Non Operating Income were $3.5 million (Q4 2025), $3.5 million (Q3 2025), and $28000.0 (Q2 2025) per Business Quant data.